The alliance will unite the strength and resources of both parties to accelerate the development of China's pharmaceutical discoveries.
HUYA is one of the first companies to have recognized China's potential to help meet the global need for new preclinical and clinical stage compounds. The company is committed to facilitating and promoting the global development and commercialization of novel pharmaceutical products originating in China. HUYA has established a series of collaborations with leading universities and research institutions throughout China and has pioneered in-licensing clinical stage compounds from the country, utilizing its expertise to advance these compounds for global markets.
Zhongshan National Health Technology Park, jointly established by the Ministry of Science and Technology, Guangdong Provincial Government and Zhongshan Municipal Government, is the first nationally designated health industrial park in China that has been built in compliance with the in ernational standards of GLP, GMP and GCP, which qualifies the development, clinical experiments and production of new medicines. Situated at the Torch Hi-tech Industrial Development Zone in Zhongshan, Guangdong,
the park has attracted numerous national and international enterprises and has formed co-operational relationships with renowned universities worldwide.
Under the agreement, Zhongshan National Health Technology Park and HUYA will collaborate to promote new drug development. HUYA may attend project promotion events and actively participate in the annual Health and Development Zhongshan Forums at the park, or organize HUYA's partners to participate in the events. HUYA may also recommend its global pharmaceutical partners to collaborate with the park.
HUYA will have the first opportunity to provide assistance in evaluating R&D projects conducted by pharmaceutical enterprises residing in the park. HUYA will be able to internationalize select programs through HUYA's innovative co-development model and the company's worldwide pharmaceutical partners, thereby introducing qualified projects from companies in the park into global markets.
"This exciting partnership between HUYA and Zhongshan National Health Technology Park will support innovation and growth of China's pharmaceutical industry," said Clement Gingras, HUYA's CTO and COO, China. "HUYA and Zhongshan National Health Technology Park share the goal of improving the health and lives of people by providing innovative pharmaceutical products."
Conghong Yu, Director of Zhongshan Health Technology Park, commented, "With HUYA's expertise in developing innovative products in accordance with international standards, this alliance will certainly aid the park's endeavor to become a nationally and internationally known health technology industrial base."
HUYA is one of the first companies to have recognized China's potential to help meet the global need for new preclinical and clinical stage compounds. The company is committed to facilitating and promoting the global development and commercialization of novel pharmaceutical products originating in China. HUYA has established a series of collaborations with leading universities and research institutions throughout China and has pioneered in-licensing clinical stage compounds from the country, utilizing its expertise to advance these compounds for global markets.
Zhongshan National Health Technology Park, jointly established by the Ministry of Science and Technology, Guangdong Provincial Government and Zhongshan Municipal Government, is the first nationally designated health industrial park in China that has been built in compliance with the in ernational standards of GLP, GMP and GCP, which qualifies the development, clinical experiments and production of new medicines. Situated at the Torch Hi-tech Industrial Development Zone in Zhongshan, Guangdong,
the park has attracted numerous national and international enterprises and has formed co-operational relationships with renowned universities worldwide.
Under the agreement, Zhongshan National Health Technology Park and HUYA will collaborate to promote new drug development. HUYA may attend project promotion events and actively participate in the annual Health and Development Zhongshan Forums at the park, or organize HUYA's partners to participate in the events. HUYA may also recommend its global pharmaceutical partners to collaborate with the park.
HUYA will have the first opportunity to provide assistance in evaluating R&D projects conducted by pharmaceutical enterprises residing in the park. HUYA will be able to internationalize select programs through HUYA's innovative co-development model and the company's worldwide pharmaceutical partners, thereby introducing qualified projects from companies in the park into global markets.
"This exciting partnership between HUYA and Zhongshan National Health Technology Park will support innovation and growth of China's pharmaceutical industry," said Clement Gingras, HUYA's CTO and COO, China. "HUYA and Zhongshan National Health Technology Park share the goal of improving the health and lives of people by providing innovative pharmaceutical products."
Conghong Yu, Director of Zhongshan Health Technology Park, commented, "With HUYA's expertise in developing innovative products in accordance with international standards, this alliance will certainly aid the park's endeavor to become a nationally and internationally known health technology industrial base."
Companies in this article
